Clinical Significance of Additional Cytogenetic Abnormalities (ACA) at Disease Progression in Patients with High-Risk Myelodysplastic Syndrome (MDS) Treated with Azacitidine

被引：0
|
作者：
Naito, Chiaki [1 ]
Shimizu, Hiroaki [2 ]
Miyazawa, Yuri [3 ]
Ishizaki, Takuma [4 ]
Yokohama, Akihiko [5 ]
Saito, Takayuki [6 ]
Tsukamoto, Norifumi [7 ]
Handa, Hiroshi [8 ]
机构：
[1] Gunma Univ Hosp, Dept Hematol, Maebashi, Gumma, Japan
[2] Gunma Univ, Dept Hematol, Grad Sch Med, Maebashi, Gunma, Japan
[3] Gunma Univ Hosp, Dept Hematol, Masbashi, Gunma, Japan
[4] Gunma Univ Hosp, Dept Hematol, Maebashi, Gumma, Japan
[5] Gunma Univ Hosp, Blood Transfus Serv, Maebashi, Gumma, Japan
[6] Gunma Univ, Grad Sch Hlth Sci, Maebashi, Gumma, Japan
[7] Gunma Univ Hosp, Ctr Oncol, Maebashi, Gumma, Japan
[8] Gunma Univ, Dept Hematol, Grad Sch Med, Maebashi, Gumma, Japan
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-127956
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5434
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Myelodysplastic Syndrome Azacitidine - useful therapeutic option in high-risk MDS
    Arnheim, Katharina
    ONKOLOGIE, 2010, 33 (12): : 720 - 721
  • [2] Impact of cytogenetic abnormalities on response to azacitidine in patients with myelodysplastic syndrome
    Iizuka, Hiroko
    Sugimoto, Keiji
    Takizawa, Haruko
    Wakabayashi, Mutsumi
    Sakajiri, Sakura
    Sekiguchi, Yasunobu
    Noguchi, Masaaki
    Komatsu, Norio
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Hospitalization rates in elderly, newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) patients treated with azacitidine.
    Ueda, Masumi
    Gupta, Divya
    Caimi, Paolo Fabrizio
    Creger, Richard
    Little, Jane
    William, Basem M.
    Lazarus, Hillard M.
    De Lima, Marcos J. G.
    Cooper, Brenda W.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Invasive Fungal Infections in Patients with High-Risk MDS and AML Treated with Azacitidine
    Pomares, Helena
    Arnan, Montserrat
    Sanchez-Ortega, Isabel
    Sureda, Anna
    Duarte, Rafael F.
    BLOOD, 2015, 126 (23)
  • [5] INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH HIGH-RISK MDS AND AML TREATED WITH AZACITIDINE
    Pomares Marin, H.
    Arnan Sangerman, M.
    Sanchez-Ortega Sanchez, I.
    Duarte Palomino, R. D.
    LEUKEMIA RESEARCH, 2015, 39 : S145 - S146
  • [6] Azacitidine therapy in high-risk myelodysplastic syndromes (MDS): A single centre experience
    Improta, S.
    Gagliardi, A.
    Villa, M. R.
    Della Cioppa, P.
    Esposito, M.
    Izzo, G. Nitrato
    Mastrullo, L.
    LEUKEMIA RESEARCH, 2013, 37 : S152 - S152
  • [7] Patient outcome measures during prolonged survival in patients (Pts) with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA)
    Santini, V.
    Fenaux, P.
    Mufti, G. J.
    Hellstroem-Lindberg, E.
    List, A. F.
    Silverman, L. R.
    Seymour, J. F.
    Backstrom, J.
    McKenzie, D.
    Beach, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Cytogenetic peripheral blood monitoring in azacitidine treated patients with high-risk MDS/sAML: A monocentric real-world experience
    Braulke, Friederike
    Schweighofer, Adrian
    Schanz, Julie
    Shirneshan, Katayoon
    Ganster, Christina
    Pollock-Kopp, Beatrix
    Leha, Andreas
    Haase, Detlef
    LEUKEMIA RESEARCH, 2023, 124
  • [9] Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome
    Nishihori, Taiga
    Perkins, Janelle
    Mishra, Asmita
    Komrokji, Rami
    Kim, Jongphil
    Kharfan-Dabaja, Mohamed A.
    Perez, Lia
    Lancet, Jeffrey
    Fernandez, Hugo
    List, Alan
    Anasetti, Claudio
    Field, Teresa
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (06) : 776 - 780
  • [10] Azacitidine prolongs survival and time to AML transformation in high-risk myelodysplastic syndrome (MDS) patients ≥65 years of age.
    Silverman, LR
    McKenzie, DR
    Peterson, BL
    Demakos, EP
    Malone, NT
    Holland, JF
    Larson, RA
    BLOOD, 2005, 106 (11) : 709A - 709A
12345